Orphazyme A/S (ORPH) received a Notice of Allowance for its US patent application 16/879,198 titled "ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS" - PatentGrants
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Orphazyme A/S (NASDAQ: ORPH) has received a Notice of Allowance for its US patent application 16/879,198 titled "ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS" - PatentGrants
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orphazyme A/S (ORPH) halted on volatility after spike higher on patent news
- Why 23andme (ME) Stock Is Up 20% Today
- Virgin Galactic (SPCE) Stock Crashes 16% on Postponed Commercial Spaceflights, Analyst Lowers PT on Increased Uncertainty and Lack of Clarity
Create E-mail Alert Related CategoriesCorporate News, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!